Bio-techne Corp · NASDAQ:TECH
Bio-techne — Merger or Acquisition (June 2018)
18 slides from Bio-techne's merger presentation, June 2018
Slide 1: Exosome Diagnostics & Quad Technologies
1 C O R P O R A T E f o c u s Exosome Diagnostics & Q u a d Te c h n o l o g i e s JUNE 2018 2018
Slide 2: Disclaimer
2 C O R P O R A T E f o c u s NASDAQ TEC H Disclaimer Cautionary Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made
Slide 3: Business Overview
3 BUSINESS OVERVIEW C O R P O R A T E f o c u s NASDAQ TEC H Revenue by Customer Segmentation OVERVIEW At a Glance: 17% President and CEO: Chuck Kummeth Phar m a/ Biot ech 36% Headquarters: M inneapolis, M N Academ i a Number of Employees: +2,000 OEM FY2017 Revenues: $563 million 25% NASDAQ: TECH Di
Slide 4: Disciplined M&A and Investment Strategy
4 D I S C I P L I N E D M & A A N D I N V E S T M E N T S T R AT E G Y C O R P O R A T E f o c u s NASDAQ TEC H • Healthy hopper of targets M&A • Sound prioritization strategy • Targets that fill gaps • Targets with ROIC > WACC 2018
Slide 5: Business Transformation: Expansion into Clinical Applications
5 E X PA N S I O N I N T O C L I N I C A L A P P L I C AT I O N S f o c u s v Foundational Business (Hematology Controls and Calibrators) T R A N S F O R M AT I O N v Legacy Biotechnology Business (Proteins, Abs & Assays) BUSINESS v Entry into ex-vivo clinical applications v Leveraging recombinant p
Slide 6: Exosome Diagnostics
6 EXOSOME DIAGNOSTICS f o c u s DIAGNOSTICS EXOSOMES EXOSOME DIAGNOSTICS 2018
Slide 7: Clinical Utility of Liquid Biopsies
7 CLINICAL UTILITY OF LIQUID BIOPSIES f o c u s Commercial Value LIQUID BIOPSY 6 1 2 3 4 5 6 Cancer Early Cancer Non-Invasive Substitute for Residual Genetic Screening Detection Treatment tissue biopsy Disease cancer among Option over where Monitoring signatures for genetically tissue biopsy samplin
Slide 8: Exosomes-Based Liquid Biopsy
8 EXOSOM ES-BASED LIQUID BIOPSY f o c u s Estimated Liquid Biopsy Market Size: $4.5 billion by 2020 EXSOMES, CTC, cfDNA v CTC & cfDNA Liquid Biopsy: v Crowded space v Quality of DNA Non-Oncology questionable • Neurodegenerative v Source of DNA unknown disease Oncology • Exosome signatures • Cardiova
Slide 9: Exosome Diagnostics - Overview
9 f o c u s EXOSOME DI AGNOSTI CS - OVERVI EW l Exosom e D iagnostics is a leading developer of biofluid-based diagnostics for precision healthcare Com pany § Launched the industry’s first RN A-based exosom e derived liquid biopsy, ExoD x Prostate IntelliScore (“EPI”), a urine-based liquid biopsy te
Slide 10: ExoDx Intelliscore (EPI)
10 EXOSOMEDX I NTELLI SCORE f o c u s F I R S T MO L E C U L A R T E S T T O P R E D I C T H I G H - G R A D E P R O S TAT E C A N C E R AT I N I T I A L B I O P S Y • Three biomarker gene expression tests to identify aggressiveness of cancer Unparalleled Performance • 34% Specificity, 92% Sensitivi
Slide 11: Reimbursement and Coverage
11 REIMBURSEMENT AND COVERAGE f o c u s qCoverage of EPI Test Milestones RE I MBURS E ME NT qCPT PLA Code (May 2017) ü qCareFirst Agreement (June 2017)- Evidence-based study-BCBS ü qMedicare Price Decision (November 2017)- PAMA price effective through 2020 ü qWorking through process to get NGS decis
Slide 12: Quad Technologies
12 QUAD TECHNOLOGIES f o c u s QUAD TECHNOLOGIES QUAD TECHNOLOGIES 2018
Slide 13: Immune Cell Therapy Workflow
13 IMMUNECELL THERAPY WORKFLOW f o c u s Abs for T-Cell Activation using QUAD CAR-T WORKFLOW technology Ella for CRS detection/monitoring Profiling CAR activity via ACD technology Assay/Ab platforms for QC GMP proteins 2018
Slide 14: Quickgel
14 QUAD TECHNOLOGIES f o c u s Q U I C KG E L 2018
Slide 15: CD/CD Cloud T Cell Expansion
15 C D 3 / C D 2 8 C L O U D z T C E L L E X PA N S I O N f o c u s TECHNOLOGIES Q UA D 2018
Slide 16: Quad Technologies Addressable Market
16 QUAD TECHNOLOGIES ADDRESABLE MARKET f o c u s CAR-T MARKET Ø Quickgel technology can address both: Ø Cell Selection Ø Cell Activation 2018
Slide 17: Key Takeaways
17 K E Y TA K E A WAY S f o c u s Exosome Quad Bio-Techne Diagnostics Technologies • Continued • Patent • Novel refocusing of protected technology to SUMMARY business into nucleic acid improve the more clinical diagnostic test CAR-T workflow platform using manufacturing • Both organic exosomes proce
Slide 18: Thank You
18 f o c u s T HANK YOU B i o - Te c h n e C o r p o r a t i o n . 614 McKinley Place . Minneapolis, Minnesota . 55413 2018